| abstract |
In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula n n n n n n n n n n or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof. |